(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -17.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Sarepta Therapeutics's revenue in 2025 is $2,481,531,000.On average, 10 Wall Street analysts forecast SRPT's revenue for 2025 to be $201,470,354,427, with the lowest SRPT revenue forecast at $191,479,253,105, and the highest SRPT revenue forecast at $211,373,709,082. On average, 10 Wall Street analysts forecast SRPT's revenue for 2026 to be $148,212,622,179, with the lowest SRPT revenue forecast at $119,835,760,363, and the highest SRPT revenue forecast at $161,944,877,902.
In 2027, SRPT is forecast to generate $145,841,019,326 in revenue, with the lowest revenue forecast at $117,949,891,010 and the highest revenue forecast at $160,181,638,913.